SIGY · Sigyn Therapeutics, Inc.
$0.03
At close · Aug 31
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$46,556
Shares
1.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.04
52W close$0.02–4.70
Avg vol 30d33K
Short int2K · 0.1% float · 1.0d
Short vol50%
DataFeb 2024–Aug 2026
Filing10-Q · Nov 14
Raw chart and full-history price indicators begin at the captured split on Jan 31, 2024; bars on opposite sides are not compared.
Up next
filed Nov 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$9,929
Trailing 12 months
Net income (TTM)
−$3.22M
Trailing 12 months
Revenue growth YoY
-88.1%
Year over year
Operating margin
-361.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$4.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.5%
Year over year · more shares
Price change (1Y)
-99.4%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−14%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−98%
trailing
YTD return
−98%
this year
Relative strength
−112%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.09% of float · ▼ -78.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
1 holders — 13F breadth
Fundamentals
Revenue growth
+406%
Y/Y
Gross margin
75%
expanding
EPS growth
+33%
Y/Y
Free cash flow
$-873.3K
Balance sheet
$2.2M
net debt
Quant / Vol
risk profile
Volatility
386%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
29.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−14%
Bearish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.09% of float · ▼ -78.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $5
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIGY
this stock
Sigyn Therapeutics, Inc.
|
$46,556 | -98.3% | +405.6% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +22.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +10.4% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.5% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +411.4% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 3.3%
- Net QoQ
- +53.0K sh
- Top holder
- Howard Capital Management…
Held
Float
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Jan 31, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIGY | -3.3% | -27.5% | -98.4% | +11.5% | -98.3% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -3.8% | -28.7% | -111.7% | +8.9% | -110.8% |